Business Context and Reporting Period
Nyxoah SA, a Belgium-based foreign private issuer, filed Form 6-K for April 2024. The report was signed on April 15, 2024, and covers the company’s April 11, 2024 announcement regarding a management appointment.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Nyxoah appointed Dr. Maurits S. Boon, MD, as Chief Medical Officer effective April 11, 2024.
- Dr. Boon joined from Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman of Education.
- He is dual board-certified in otolaryngology and sleep medicine.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, material risk updates, contingencies, or unusual financial items. The appointment may support the company’s medical and clinical leadership, but the filing does not quantify any expected business or financial impact.
The appointment disclosure is incorporated by reference into specified Form S-8 and Form F-3 registration statements. Exhibit 99.1, the related press release, is furnished and is generally not deemed filed under Section 18 of the Exchange Act or incorporated into other filings except where expressly provided.
Facts Investors Should Verify
- Dr. Boon’s responsibilities, compensation, employment terms, and any related-party considerations.
- Any subsequent disclosures regarding the effect of the appointment on clinical development, regulatory activities, or commercialization.
- Nyxoah’s latest reported revenue, cash balance, cash-burn rate, debt, liquidity runway, and financing plans, which are not included in this Form 6-K.
- The contents of Exhibit 99.1, the April 11, 2024 press release.